Christopher Yea
CHIEF DEVELOPMENT OFFICER · KalVista Pharmaceuticals, Inc.
- 2024
- Jun 11, 2026
- 16
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Christopher Yea files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Venrock Healthcare Capital Partners III, L.P. - $3.69M in KALV purchases and sales in the last 12 months
- Benjamin L. Palleiko - $1.19M in KALV purchases and sales in the last 12 months
- Paul K. Audhya - $430K in KALV purchases and sales in the last 12 months
- Nicole Sweeny - $241K in KALV purchases and sales in the last 12 months
- Brian Piekos - $165K in KALV purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Christopher Yea?
Christopher Yea is a corporate insider, tracked as CHIEF DEVELOPMENT OFFICER of KalVista Pharmaceuticals, Inc. (KALV). InsiderAlpha holds 16 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
When did Christopher Yea last file a Form 4?
The most recent primary Form 4 on record is dated 11 June 2026, one of 16 filings going back to 2024.
Has Christopher Yea been buying or selling stock?
Recorded transactions: 0 open-market purchases and 14 open-market sales ($1.89M) across all tracked filings.
